Trial Profile
A Single-arm, Multi-center Phase II Trial of Bendamustine/Rituximab Induction Followed by Venetoclax and Rituximab Consolidation for the Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2025.
- 12 Dec 2023 Updated results assessing safety and efficacy of BR-VR in previously untreated CLL patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Jul 2023 Status changed from recruiting to active, no longer recruiting.